United Nations. 2003. World Population Prospects: The 2002 Revision. New York: Population Division, Department of Economic and Social Affairs, United Nations.
U.S. Census Bureau. 2000. U.S. Census 2000. Washington, DC: U.S. Bureau of the Census.
USPHS/IDSA (U.S. Public Health Service/Infectious Diseases Society of America) Prevention of Opportunistic Infections Working Group. 2001. 2001 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. HIV Clinical Trials 2(6):493–554.
Vlahov D, Brewer F, Munoz A, Hall D, Taylor E, Polk BF. 1989. Temporal trends of human immunodeficiency virus type 1 (HIV-1) infection among inmates entering a statewide prison system, 1985–1987. Journal of Acquired Immune Deficiency Syndromes 2(3):283–290.
Vlahov D, Graham N, Hoover D, Flynn C, Bartlett JG, Margolick JB, Lyles CM, Nelson KE, Smith D, Holmberg S, Farzadegan H. 1998. Prognostic indicators for AIDS and infectious disease death in HIV-infected injection drug users: plasma viral load and CD4+ cell count. Journal of the American Medical Association 279(1):35–40.
Volberding PA, Lagakos SW, Koch MA, Pettinelli C, Myers MW, Booth DK, Balfour HH Jr, Reichman RC, Bartlett JA, Hirsch MS. 1990. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer that 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. New England Journal of Medicine 322(14):941–949.
Weis SE, Moonan PK, Pogoda JM, Turk L, King B, Freeman-Thompson S, Burgess G. 2001. Tuberculosis in the foreign-born population of Tarrant county, Texas by immigration status. American Journal of Respiratory and Critical Care Medicine 164(6):953–957.
Welch K, Morse A. 2001. Survival patterns among HIV+ individuals based on health care utilization. Journal of the National Medical Association 93(6):214–219.
Wensing AMJ, van de Viver DAMC, Asjo B, Balotta C, Camacho R, de Luca A, de Mendoza C, Deroo S, Derdelinckx I, Grossman Z, Hamouda O, Hatzakis A, Hoepelman A, Horban A, Korn K, Kuecherer C, Leitner T, Nielsen C, Ormasson V, Perrin L, Paraskevix D, Puchhammer E, Roman F, Ruiz L, Salminen M, Schmit JCC, Soriano V, Stanczak G, Stanojevic M, Vandamme AM, Van Laethem K, Violin M, Yerly S, Zazzi M, Boucher CAB. 2003. Analysis from more than 1600 newly diagnosed patients with HIV from 17 European countries shows that 10% of the patients carry primary drug resistance: The CATCH-Study. The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Abstract no. LB01. [Online]. Available: http://www.ias.se/abstract/show.asp?abstract_id=111122 [accessed September 28, 2003].
Wilson TE, Massad LS, Riester KA, Barkan S, Richardson J, Young M, Gurtman A, Greenblatt R. 1999. Sexual, contraceptive, and drug use behaviors of women with HIV and those at high risk for infection: results from the Women’s Intergency HIV Study. AIDS 13(5):591–598.